Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations: 2021-2024

Historic Income from Continuing Operations for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$301.4 million.

  • Amylyx Pharmaceuticals' Income from Continuing Operations rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.9 million, marking a year-over-year increase of 42.66%. This contributed to the annual value of -$301.4 million for FY2024, which is 714.44% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Income from Continuing Operations stood at -$301.4 million, which was down 714.44% from $49.0 million recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Income from Continuing Operations peaked at $49.0 million during FY2023, and registered a low of -$301.4 million during FY2024.
  • Its 3-year average for Income from Continuing Operations is -$150.6 million, with a median of -$199.5 million in 2022.
  • In the last 5 years, Amylyx Pharmaceuticals' Income from Continuing Operations soared by 124.59% in 2023 and then tumbled by 714.44% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$87.9 million in 2021, then slumped by 126.86% to -$199.5 million in 2022, then spiked by 124.59% to $49.0 million in 2023, then crashed by 714.44% to -$301.4 million in 2024.